Certain dosage strengths of Wegovy (semaglutide) will be in short supply through September 2023, according to Novo Nordisk.

Wegovy is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least 1 weight-related comorbid condition (eg, hypertension, type 2 diabetes mellitus, or dyslipidemia); and in pediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and sex (obesity).

Wegovy is supplied in a prefilled, single-dose pen in 5 dosage strengths: 0.25 mg/0.5 mL, 0.5 mg/0.5 mL, 1 mg/0.5 mL, 1.7 mg/0.75 mL, and 2.4 mg/0.75 mL.  Novo Nordisk noted that while the capacity of production has increased, the supply of the 0.25-mg, 0.5-mg, and 1-mg dosage strengths will likely be limited through September. With regard to the 1.7-mg and 2.4-mg dosages, the Company does not anticipate supply interruptions for these dosage strengths.

Continue Reading

In a letter to health care providers, the Company recommended that “health care providers take into consideration the limited supply of the 0.25 mg, 0.5 mg, and 1 mg dose strengths of Wegovy as part of their decision-making when initiating new patients on therapy, recognizing the possibility of disruption in care.”

This article originally appeared on MPR